ADHD symptoms · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes ADHD symptoms: all parallel‐group trials and first‐period cross‐over… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious (penicillin versus doxycycline) · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more adverse events… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
General behaviour: all parallel‐group trials and first‐period cross‐over trials General behaviour rating scales (Teacher‐rated) · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes general behaviour: all parallel‐group trials and first‐period… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
QoL · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes quality of life (parent‐rated) compared with placebo or no intervention (very low certainty).
1 finding from 1 review
ADHD symptom‐related behavior Measured by standardized rating scales: Conners' Abbreviated Teacher Rating Scale, Conners' Abbreviated Parent Rating Scale, IOWA Conners' Teacher Rating Scale, Conners' Continuous Performance Task, Child Behaviour Ch... · children with ADHD and comorbid tic disorders
1 finding from 1 review
Tic severity Measured by standardized rating scales: Yale Global Tic Severity Scale, Tourette Syndrome Severity Scale, Global Tic Rating Scale, Tic Symptom Self‐Report, Hopkins Motor/Vocal Scale · children with ADHD and comorbid tic disorders
1 finding from 1 review
Change in apathy · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease
Methylphenidate showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in NPS · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Change in cognition · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Change in functional performance · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Change in global disease severity · Apathy in people with mild‐to‐moderate Alzheimer's disease
Methylphenidate showed no clear difference in change in global disease severity compared with placebo (moderate certainty).
1 finding from 1 review
Leaving the study early · Apathy in people with mild‐to‐moderate Alzheimer's disease
Methylphenidate showed no clear difference in dropouts compared with placebo (low certainty).
1 finding from 1 review
Inattention Measured using SNAP‐IV inattention subscale (range 0 to 27) · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impulsivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Hyperactivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impaired social interaction · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impaired communication · Children aged 6 to 18 years with ASD
2 findings from 1 review
Stereotypical behaviours · Children aged 6 to 18 years with ASD
2 findings from 1 review